A Phase 2 interventional study of Natrunix 400 mg and Placebo in Rheumatoid Arthritis, sponsored by XBiotech, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by XBiotech, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 63rd largest by planned enrollment, is the only one that started in 2026, is one of 10 in phase 2, and was the 110th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
XBiotech, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
XBiotech, Inc. has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Approximately 108 subjects will be randomized in 2 arms in 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks. At the week 14 visit subjects in both arms will undergo a safety follow up visit OR begin receiving biweekly subcutaneous injections of 400mg Natrunix for 14 weeks as part of an Open Label Extension (OLE).
The study will last for a maximum of 33 weeks, including: a screening period of up to 4 weeks, a 14-week double-blinded treatment phase followed by a 14-week open label extension phase and one-week follow-up.
Number of Planned Subjects: Approximately 108 subjects within 2 arms randomized 2:1 [400 mg Natrunix + MTX weekly (n=72) or placebo + MTX weekly arms (n=36)].
Study Duration: The study will last for a maximum of 33 weeks, including: a screening period of up to 4 weeks, a 14-week double-blinded treatment phase followed by a 14-week open label extension phase and one-week follow-up.
Study Design: Subjects will be randomized into the study in a 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks. At the week 14 visit subjects in both arms will undergo a safety follow up visit OR begin receiving biweekly subcutaneous injections of 400mg Natrunix for 14 weeks as part of an Open Label Extension (OLE).
Subjects will undergo a preliminary assessment for study eligibility. Subjects who meet pre-screening requirements may then provide informed consent to acknowledge understanding of and accept enrollment into the clinical study. Subjects enrolled in the study will be taking concomitant methotrexate, have a diagnosis of moderate to severe RA according to 2010 ACR/EULAR classification criteria and have ≥6 swollen joints (based on DAS28), ≥6 tender joints (based on DAS28) and DAS-ESR > 3.2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must be methotrexate-inadequate responders.
a. Persistent moderate to severe RA disease activity (i.e., criteria #2 above) despite ongoing treatment with MTX.
Exclusion Criteria:
laboratory abnormalities, including:
Evidence of active , , or infection.
Any other concomitant disease, disorder, or condition that could interfere with the interpretation of study endpoints, or the patient's ability to participate in and complete the study, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 400mg Natrunix and MTX weekly
Biological: Natrunix 400 mg · Drug: Methotrexate (MTX)
Subjects will receive placebo and MTX weekly
Drug: Placebo · Drug: Methotrexate (MTX)
The active ingredient of Natrunix is an IgG4 monoclonal antibody indistinguishable from that naturally occurring in an IL-1a-immune healthy human. Natrunix is formulated as 200 mg/mL sterile liquid in a stabilizing isotonic formulation buffered to pH 7.0. The product is filled into a 2 mL glass pre-filled syringe suitable for subcutaneous injection. The drug product is formulated and buffered to a neutral body pH of 7.0.
Also known as: methotrexate
Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product
Methotrexate may be administered in pill form by mouth, as liquid by mouth, or by subcutaneous injection.Subjects enrolled in this study should be receiving a stable minimum weekly dose of 10mg. Weekly methotrexate should not exceed 25 mg/week.
ACR 20 response
The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.
Time frame: at 14 weeks from baseline
ACR 50 response rate
The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.
Time frame: at 14 weeks from baseline
Mean change in number of swollen and tender joints based on 66/68-joint count
Subject's tender and swollen joint will be counted by investigators
Time frame: at 14 weeks from baseline
Mean change in NRS-pain score
Subjects will rate the pain score everyday between 7-10pm, where 0 is no pain and 10 is maximum pain
Time frame: at 14 weeks from baseline
ACR 70 response rate
The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.
Time frame: at 2, 4, 8, 12 and 14 weeks from baseline
ACR 20 response rate
The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.
Time frame: at 2, 4, 8 and 12 weeks from baseline
ACR 50 response rate
The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.
Time frame: at 2, 4, 8 and 12 weeks from baseline
Mean change in HAQ-DI score
HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) DISABILITY INDEX (DI): This questionnaire is used in this study which has 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities subjects will be assessed on. In each section, 0 represents without any difficulty and 3 represents task cannot be done at all. In each section, if one question is scored 1 and another 2, then the score for the section is 2. If an aid or device is used or if help is required from another individual, then the minimum score for that section is 2. If the section score is already 2 or more then no modification is made. If any task is not applicable, it can be left blank by the subject.
Time frame: at 2, 4, 8, 12 and 14 weeks from baseline
Mean change in NRS-pain score
Subjects will rate the pain score everyday between 7-10pm, where 0 is no pain and 10 is maximum pain
Time frame: at 2, 4, 8 and 12 weeks from baseline
Mean change in RAPID-3 score
The RAPID3 (Routine Assessment of Patient Index Data 3) is an index of data set measures to assess disease severity. Each measure is scored 0 to 10, for a total of 30. Higher RAPID3 scores correlate with higher disease severity (\>12 = high; 6.1-12 = moderate; 3.1-6 = low; \< 3 = remission).
Time frame: at 2, 4, 8, 12 and 14 weeks from baseline
Mean change in the PGA score
A patient global assessment (PGA) score is a single question with a 0 to 10 response. Higher scores represent a higher level of disease activity or a worse global health.
Time frame: at 2, 4, 8, 12 and 14 weeks from baseline
Mean change in the EGA score
The evaluator global assessment (EGA) score is a single question used to assess how well a patient is doing regarding the status of a disease. This is scored 0-10, higher scores represent worse activity.
Time frame: at 2, 4, 8, 12 and 14 weeks from baseline
Mean change in number of swollen and tender joints based on 66/68-joint count
Subject's tender and swollen joint will be counted by investigators
Time frame: at 2, 4, 8, and 12 weeks from baseline
Mean change in the CDAI score
The Clinical Disease Activity Index (CDAI) is a composite index for assessing disease activity, it is based on the count of swollen/tender joint count of 28 joints along with patient and evaluator global assessments. The CDAI has a range of 0 -76 and can be classified as: remission (≤2.8), low disease activity (2.9-10), moderate disease activity (10.1-22), and high disease activity (\>22).
Time frame: at 2, 4, 8, 12 and 14 weeks from baseline
Mean change in DAS28-ESR score
The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease: \<2.6: Remission 2.6-3.2: Low disease activity 3.2-5.1: Moderate disease activity \>5.1: High disease activity
Time frame: at 2, 4, 8, 12 and 14 weeks from baseline
Percentage of patients with Low Disease Activity (DAS-ESR <3.2; CDAI > 2.8 & ≤ 10)
The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease. The Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis determines severity of rheumatoid arthritis
Time frame: at 2, 4, 8, 12 and 14 weeks from baseline
Occurence of AEs and SAEs in subjects during the trial
Subjects will be monitored for any adverse events or serious adverse reactions due to study drug
Time frame: until 28 weeks from baseline
Any abnormality in Physical examination will be monitored
Physical examination is the process of evaluating objective anatomic findings through the use of observation, palpation, percussion, and auscultation.
Time frame: until 28 weeks from baseline
Any clinically significant changes in vital signs from normality will be assessed
Vital signs are measurements of the body's most basic functions, such as breathing rate, heart rate, body temperature, and blood pressure.
Time frame: until 28 weeks from baseline
Any abnormal laboratory tests will be monitored
Laboratory test is a medical procedure that involves testing a sample of blood, urine, or other substance from the body.
Time frame: until 28 weeks from baseline
ACR 20 response rate
The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.
Time frame: at 22 and 28 OLE weeks
ACR 50 response rate
The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.
Time frame: at 22 and 28 OLE weeks
ACR 70 response rate
The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.
Time frame: at 22 and 28 OLE weeks
Mean change in number of swollen and tender joints based on 66/68-joint count
Subject's tender and swollen joint will be counted by investigators
Time frame: at 22 and 28 OLE weeks
Mean change in NRS-pain score
Subjects will rate the pain score everyday between 7-10pm, where 0 is no pain and 10 is maximum pain
Time frame: at 22 and 28 OLE weeks
Mean change in HAQ-DI score
HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) DISABILITY INDEX (DI): This questionnaire is used in this study which has 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities subjects will be assessed on. In each section, 0 represents without any difficulty and 3 represents task cannot be done at all. In each section, if one question is scored 1 and another 2, then the score for the section is 2. If an aid or device is used or if help is required from another individual, then the minimum score for that section is 2. If the section score is already 2 or more then no modification is made. If any task is not applicable, it can be left blank by the subject.
Time frame: at 22 and 28 OLE weeks
Mean change in RAPID-3 score
The RAPID3 (Routine Assessment of Patient Index Data 3) is an index of data set measures to assess disease severity. Each measure is scored 0 to 10, for a total of 30. Higher RAPID3 scores correlate with higher disease severity (\>12 = high; 6.1-12 = moderate; 3.1-6 = low; \< 3 = remission).
Time frame: at 22 and 28 OLE weeks
Mean change in the PGA score
A patient global assessment (PGA) score is a single question with a 0 to 10 response. Higher scores represent a higher level of disease activity or a worse global health.
Time frame: at 22 and 28 OLE weeks
Mean change in the EGA score
The evaluator global assessment (EGA) score is a single question used to assess how well a patient is doing regarding the status of a disease. This is scored 0-10, higher scores represent worse activity.
Time frame: at 22 and 28 OLE weeks
Mean change in the CDAI score
The Clinical Disease Activity Index (CDAI) is a composite index for assessing disease activity, it is based on the count of swollen/tender joint count of 28 joints along with patient and evaluator global assessments. The CDAI has a range of 0 -76 and can be classified as: remission (≤2.8), low disease activity (2.9-10), moderate disease activity (10.1-22), and high disease activity (\>22).
Time frame: at 22 and 28 OLE weeks
Mean change in DAS28-ESR score
The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease: \<2.6: Remission 2.6-3.2: Low disease activity 3.2-5.1: Moderate disease activity \>5.1: High disease activity
Time frame: at 22 and 28 OLE weeks
Percentage of patients with Low Disease Activity (DAS-ESR <3.2; CDAI > 2.8 & ≤ 10)
The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease. The Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis determines severity of rheumatoid arthritis
Time frame: at 22 and 28 OLE weeks
Assessment of Maximum Plasma Concentration
Blood samples will be collected from subjects. Maximum Plasma Concentration (Cmax) measurement of Natrunix will be performed in all enrolled participants.
Time frame: at baseline (pre-treatment) until week 14
Number of participants with Anti-Drug Antibodies
Blood samples will also be used to test for the presence of treatment emergent anti-drug antibodies (ADA) against Natrunix. XBiotech has developed an ELISA method to perform quantitative and qualitative measurements of ADA.
Time frame: at baseline (pre-treatment) until week 14
ECG QTc interval
An electrocardiogram (ECG or EKG) is a non-invasive test that records the cardiac electrical activity. QTc(ms) value will be collected along with a clinical interpretation. A normal QTc interval on an ECG, is generally considered to be between 350 and 450 milliseconds (ms) for men and 360 to 460 ms for women. Any abnormalities in ECG will be recorded during study from baseline.
Time frame: until 28 weeks from baseline
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jan 2027, 6 months later.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 6 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate
XBiotech, Inc.